Combatting antifungal resistance: Paradigm shift in the diagnosis and management of onychomycosis and dermatomycosis.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
18
11
2022
accepted:
26
04
2023
medline:
28
8
2023
pubmed:
21
5
2023
entrez:
21
5
2023
Statut:
ppublish
Résumé
Antifungal resistance has become prevalent worldwide. Understanding the factors involved in spread of resistance allows the formulation of strategies to slow resistance development and likewise identify solutions for the treatment of highly recalcitrant fungal infections. To investigate the recent explosion of resistant strains, a literature review was performed focusing on four main areas: mechanisms of resistance to antifungal agents, diagnosis of superficial fungal infections, management, and stewardship. The use of traditional diagnostic tools such as culture, KOH analysis and minimum inhibitory concentration values on treatment were investigated and compared to the newer techniques such as molecular methods including whole genome sequencing, and polymerase chain reaction. The management of terbinafine-resistant strains is discussed. We have emphasized the need for antifungal stewardship including increasing surveillance for resistant infection.
Substances chimiques
Antifungal Agents
0
Terbinafine
G7RIW8S0XP
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1706-1717Informations de copyright
© 2023 European Academy of Dermatology and Venereology.
Références
Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17:e383-92.
Kuehn BM. Progress against antimicrobial resistance has slipped. JAMA. 2022;328:702-2.
Astvad KMT, Hare RK, Jørgensen KM, Saunte DML, Thomsen PK, Arendrup MC. Increasing terbinafine resistance in Danish Trichophyton isolates 2019-2020. J Fungi. 2022;8:150.
Ebert A, Monod M, Salamin K, Burmester A, Uhrlaß S, Wiegand C, et al. Alarming India-wide phenomenon of antifungal resistance in dermatophytes: a multicentre study. Mycoses. 2020;63:717-28.
Noguchi H, Matsumoto T, Hiruma M, Kimura U, Kano R, Yaguchi T, et al. Tinea unguium caused by terbinafine-resistant Trichophyton rubrum successfully treated with fosravuconazole. J Dermatol. 2019;46:e446-7.
Suzuki S, Mano Y, FuruyA N, Fujitani K. Discovery of terbinafine low susceptibility Trichophyton rubrum strain in Japan. Biocontrol Sci. 2018;23:151-4.
Kakurai M, Harada K, Maeda T, Hiruma J, Kano R, Demitsu T. Case of tinea corporis due to terbinafine-resistant Trichophyton interdigitale. J Dermatol. 2020;47:e104-5.
Kimura U, Hiruma M, Kano R, Matsumoto T, Noguchi H, Takamori K, et al. Caution and warning: arrival of terbinafine-resistant Trichophyton interdigitale of the Indian genotype, isolated from extensive dermatophytosis, in Japan. J Dermatol. 2020;47:e192-3.
Hiruma J, Noguchi H, Hase M, Tokuhisa Y, Shimizu T, Ogawa T, et al. Epidemiological study of terbinafine-resistant dermatophytes isolated from Japanese patients. J Dermatol. 2021;48:564-7.
Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009). Int J Antimicrob Agents. 2011;38:65-9.
Moreno-Sabater A, Normand A-C, Bidaud A-L, Cremer G, Foulet F, Brun S, et al. Terbinafine resistance in dermatophytes: A French multicenter prospective study. J Fungi. 2022;8:220.
Kong X, Tang C, Singh A, Ahmed SA, Al-Hatmi AM, Chowdhary A, et al. Antifungal susceptibility and mutations in the squalene epoxidase gene in dermatophytes of the Trichophyton mentagrophytes species complex. Antimicrob Agents Chemother. 2021;65:e0005621.
Burmester A, Hipler UC, Elsner P, Wiegand C. Point mutations in the squalene epoxidase erg1 and sterol 14-α demethylase erg11 gene of T indotineae isolates indicate that the resistant mutant strains evolved independently. Mycoses. 2022;65:97-102.
Süß A, Uhrlass S, Ludes A, Verma SB, Monod M, Krueger C, et al. Extensive tinea corporis due to a terbinafine-resistant Trichophyton mentagrophytes isolate of the Indian genotype in a young infant from Bahrain in Germany. Hautarzt. 2019;70:888-96.
Nenoff P, Verma SB, Ebert A, Süß A, Fischer E, Auerswald E, et al. Spread of terbinafine-resistant trichophyton mentagrophytes type VIII (India) in Germany-“the tip of the iceberg?”. J Fungi. 2020;6:207.
Hsieh A, Quenan S, Riat A, Toutous-Trellu L, Fontao L. A new mutation in the SQLE gene of Trichophyton mentagrophytes associated to terbinafine resistance in a couple with disseminated tinea corporis. J Mycol Med. 2019;29:352-5.
Yamada T, Maeda M, Alshahni MM, Tanaka R, Yaguchi T, Bontems O, et al. Terbinafine resistance of Trichophyton clinical isolates caused by specific point mutations in the squalene epoxidase gene. Antimicrob Agents Chemother. 2017;61:e00115-17.
Wingfield Digby SS, Hald M, Arendrup MC, Hjorth SV, Kofoed K. Darier disease complicated by terbinafine-resistant Trichophyton rubrum: a case report. Acta Derm Venereol. 2017;97:139-40.
Schøsler L, Andersen LK, Arendrup MC, Sommerlund M. Recurrent terbinafine resistant Trichophyton rubrum infection in a child with congenital ichthyosis. Pediatr Dermatol. 2018;35:259-60.
Łagowski D, Gnat S, Nowakiewicz A, Osińska M, Dyląg M. Intrinsic resistance to terbinafine among human and animal isolates of Trichophyton mentagrophytes related to amino acid substitution in the squalene epoxidase. Infection. 2020;48:889-97.
Sacheli R, Harag S, Dehavay F, Evrard S, Rousseaux D, Adjetey A, et al. Belgian national survey on tinea capitis: epidemiological considerations and highlight of terbinafine-resistant T. mentagrophytes with a mutation on SQLE gene. J Fungi. 2020;6:195.
Siopi M, Efstathiou I, Theodoropoulos K, Pournaras S, Meletiadis J. Molecular epidemiology and antifungal susceptibility of Trichophyton isolates in Greece: emergence of terbinafine-resistant Trichophyton mentagrophytes type VIII locally and globally. J Fungi. 2021;7:419.
Gu D, Hatch M, Ghannoum M, Elewski BE. Treatment-resistant dermatophytosis: a representative case highlighting an emerging public health threat. JAAD Case Reports. 2020;6:1153-5.
Ngo TMC, Nu PAT, Cao LC, Ha TNT, Do TBT, Thi GT. A case of onychomycosis caused by a terbinafine-susceptible Fusarium solani in Vietnam. Iran J Microbiol. 2022;14:932-6.
Taghipour S, Shamsizadeh F, Pchelin IM, Rezaei-Matehhkolaei A, Zarei Mahmoudabadi A, Valadan R, et al. Emergence of terbinafine resistant Trichophyton mentagrophytes in Iran, harboring mutations in the squalene epoxidase (SQLE) gene. Infect Drug Resist. 2020;13:845-50.
Firooz A, Daneshpazhooh M, Lotfali E, Sharzad Kavkani M, Ghasemi Z, Khamesipoor A, et al. Drug sensitivity profile of fungi isolated from onychomycosis patients and evaluation of squalene epoxidase mutation in one terbinafine-resistant Trichophyton mentagrophytes species. Microb Drug Resist. 2021;27:1658-63.
Salehi Z, Shams-Ghahfarokhi M, Razzaghi-Abyaneh M. Antifungal drug susceptibility profile of clinically important dermatophytes and determination of point mutations in terbinafine-resistant isolates. Eur J Clin Microbiol Infect Dis. 2018;37:1841-6.
Verma SB. Emergence of recalcitrant dermatophytosis in India. Lancet Infect Dis. 2018;18:718-9.
Verma S, Madhu R. The great Indian epidemic of superficial dermatophytosis: an appraisal. Indian J Dermatol. 2017;62:227.
Martinez-Rossi NM, Bitencourt TA, Peres NT, Lang EA, Gomes EV, Quaresemin NR, et al. Dermatophyte resistance to antifungal drugs: mechanisms and prospectus. Front Microbiol. 2018;9:1108.
Meneau I, Sanglard D. Azole and fungicide resistance in clinical and environmental Aspergillus fumigatus isolates. Med Mycol. 2005;43:S307-11.
Arastehfar A, Carvalho A, van de Veerdonk FL, Jenks JD, Koehler P, Krause R, et al. COVID-19 associated pulmonary aspergillosis (CAPA)-from immunology to treatment. J Fungi. 2020;6:91.
Singh A, Masih A, Khurana A, Singh PK, Gupta M, Hagen F, et al. High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. Mycoses. 2018;61:477-84.
Rudramurthy SM, Shankarnarayan SA, Dogra S, Shaw D, Mushtaq K, Paul RA, et al. Mutation in the squalene epoxidase gene of Trichophyton interdigitale and Trichophyton rubrum associated with allylamine resistance. Antimicrob Agents Chemother. 2018;62:e02522-17.
Monod M, Feuermann M, Salamin K, Fratti M, Makino M, Alshahni MM, et al. Trichophyton rubrum azole resistance mediated by a new ABC transporter, TruMDR3. Antimicrob Agents Chemother. 2019;63:e00863-19.
Singh A, Masih A, Monroy-Nieto J, Singh PK, Bowers J, Travis J, et al. A unique multidrug-resistant clonal Trichophyton population distinct from Trichophyton mentagrophytes/Trichophyton interdigitale complex causing an ongoing alarming dermatophytosis outbreak in India: Genomic insights and resistance profile. Fungal Genet Biol. 2019;133:103266.
Gaurav V, Bhattacharya S, Sharma N, Datt S, Kumar P, Rai G, et al. Terbinafine resistance in dermatophytes: time to revisit alternate antifungal therapy. J Med Mycol. 2021;31:101087.
Fattahi A, Shirvani F, Ayatollahi A, Rezaei-Matehkolaei A, Badali H, Lotfali E, et al. Multidrug-resistant Trichophyton mentagrophytes genotype VIII in an Iranian family with generalized dermatophytosis: report of four cases and review of literature. Int J Dermatol. 2021;60:686-92.
Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25-31.
Burmester A, Hipler UC, Uhrlaß S, Nenoff P, Singal A, Verma SB, et al. Indian Trichophyton mentagrophytes squalene epoxidase erg1 double mutants show high proportion of combined fluconazole and terbinafine resistance. Mycoses. 2020;63:1175-80.
Monod M, Feuermann M, Yamada T. Terbinafine and itraconazole resistance in dermatophytes. In: Bouchara J-P, Gupta AK, Nenoff P, Chaturvedi V, editors. Dermatophytes and dermatophytoses. Switzerland: Springer; 2021. p. 415-29.
Gupta AK, Talukder M, Venkataraman M. Review of the alternative therapies for onychomycosis and superficial fungal infections: posaconazole, fosravuconazole, voriconazole, oteseconazole. Int J Dermatol. 2021;61:1431-41.
Gupta AK, Venkataraman M, Renaud HJ, Summerbell R, Shear NH, Piguet V. The increasing problem of treatment-resistant fungal infections: a call for antifungal stewardship programs. Int J Dermatol. 2021;60:e474-9.
Gupta AK, Venkataraman M. Antifungal resistance in superficial mycoses. J Dermatolog Treat. 2022;33:1888-95.
Shen JJ, Arendrup MC, Verma S, Saunte DML. The emerging terbinafine-resistant Trichophyton epidemic: what is the role of antifungal susceptibility testing? Dermatology. 2022;238:60-79.
Khurana A, Sardana K, Chowdhary A. Antifungal resistance in dermatophytes: recent trends and therapeutic implications. Fungal Genet Biol. 2019;132:103255.
Saunte DML, Pereiro-Ferreirós M, Rodríguez-Cerdeira C, Sergeev AY, Arabatzis M, Prohić A, et al. Emerging antifungal treatment failure of dermatophytosis in Europe: take care or it may become endemic. J Eur Acad Dermatol Venereol. 2021;35:1582-6.
Nowosielski M, Hoffmann M, Wyrwicz LS, Stepniak P, Plewczynski DM, Lazniewski M, et al. Detailed mechanism of squalene epoxidase inhibition by terbinafine. J Chem Inf Model. 2011;51:455-62.
Martins MP, Rossi A, Sanches PR, Martinez-Rossi NM. Differential expression of multidrug-resistance genes in Trichophyton rubrum. J Integr OMICS. 2019;9:65-9.
Cervelatti EP, Fachin AL, Ferreira-Nozawa MS, Martinez-Rossi NM. Molecular cloning and characterization of a novel ABC transporter gene in the human pathogen Trichophyton rubrum. Med Mycol. 2006;44:141-7.
Martins MP, Franceschini ACC, Jacob TR, Rossi A, Martinez-Rossi NM. Compensatory expression of multidrug-resistance genes encoding ABC transporters in dermatophytes. J Med Microbiol. 2016;65:605-10.
Fachin AL, Ferreira-Nozawa MS, Maccheroni W, Martinez-Rossi NM. Role of the ABC transporter TruMDR2 in terbinafine, 4-nitroquinoline N-oxide and ethidium bromide susceptibility in Trichophyton rubrum. J Med Microbiol. 2006;55:1093-9.
Kano R. ATP-Binding Cassette (ABC) transporter proteins in highly terbinafine-resistant strains of Trichophyton indotineae (former species name: Trichophyton interdigitale). Med Mycol J. 2021;62:21-5.
Kano R, Hsiao YH, Han HS, Chen C, Hasegawa A, Kamata H. Resistance mechanism in a terbinafine-resistant strain of Microsporum canis. Mycopathologia. 2018;183:623-7.
Gnat S, Łagowski D, Nowakiewicz A, Dyląg M, Osińska M. Complementary effect of mechanism of multidrug resistance in Trichophyton mentagrophytes isolated from human dermatophytoses of animal origin. Mycoses. 2021;64:537-49.
Kano R, Kimura U, Kakurai M, Hiruma J, Kamata H, Suga Y, et al. Trichophyton indotineae sp. nov.: a new highly terbinafine-resistant anthropophilic dermatophyte species. Mycopathologia. 2020;185:947-58.
Tang C, Kong X, Ahmed SA, Thakur R, Chowdhary A, Nenoff P, et al. Taxonomy of the Trichophyton mentagrophytes/T. interdigitale species complex harboring the highly virulent, multiresistant genotype T. indotineae. Mycopathologia. 2021;186:315-26.
Santos HL, Lang EAS, Segato F, Rossi A, Martinez-Rossi NM. Terbinafine resistance conferred by multiple copies of the salicylate 1-monooxygenase gene in Trichophyton rubrum. Med Mycol. 2018;56:378-81.
Graminha MA, Rocha EM, Prade RA, Martinez-Rossi NM. Terbinafine resistance mediated by salicylate 1-monooxygenase in Aspergillus nidulans. Antimicrob Agents Chemother. 2004;48:3530-5.
Nett JE, Crawford K, Marchillo K, Andes DR. Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob Agents Chemother. 2010;54:3505-8.
Desai JV, Mitchell AP. Candida albicans biofilm development and its genetic control. Microbiol Spectr. 2015;3:3.
Mourad A, Stiber JA, Perfect JR, Johnson MD. Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone. J Antimicrob Chemother. 2019;74:228-33.
Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201-11.
Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007;109:1532-5.
Appelt L, Nenoff P, Uhrlaß S, Krüger C, Kühn P, Eichhorn K, et al. Terbinafine-resistant dermatophytoses and onychomycosis due to Trichophyton rubrum. Hautarzt. 2021;72:868-77.
Saunte DML, Piraccini BM, Sergeev AY, Prohić A, Sigurgeirsson B, Rodríguez-Cerdeira C, et al. A survey among dermatologists: diagnostics of superficial fungal infections - what is used and what is needed to initiate therapy and assess efficacy? J Eur Acad Dermatol Venereol. 2019;33:421-7.
Ameen M, Lear JT, Madan V, Mohd Mustapa MF, Richardson M. British Association of Dermatologists' guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014;171:937-58.
Gupta AK, Venkataraman M, Hall DC, Cooper EA, Summerbell RC. The emergence of Trichophyton indotineae: implications for clinical practice. Int J Dermatol. 2023;62:857-61.
Gupta AK, Hall DC, Cooper EA, Ghannoum MA. Diagnosing onychomycosis: what's new? J Fungi. 2022;8:464.
Yamada T, Yaguchi T, Maeda M, Alshahni MM, Salamin K, Guenova E, et al. Gene amplification of CYP51B: a new mechanism of resistance to azole compounds in Trichophyton indotineae. Antimicrob Agents Chemother. 2022;66:e0005922.
Shankarnarayan SA, Shaw D, Sharma A, Chakrabarti A, Dogra S, Kumaran MS, et al. Rapid detection of terbinafine resistance in Trichophyton species by amplified refractory mutation system-polymerase chain reaction. Sci Rep. 2020;10:1297.
Nenoff P, Uhrlaß S, Verma SB, Panda S. Trichophyton mentagrophytes ITS genotype VIII and Trichophyton indotineae: a terminological maze, or is it? Indian J Dermatol Venereol Leprol. 2022;88:586-9.
Saunte DML, Hare RK, Jørgensen KM, Jørgensen R, Deleuran M, Zachariae CO, et al. Emerging terbinafine resistance in Trichophyton: clinical characteristics, squalene epoxidase gene mutations, and a reliable EUCAST method for detection. Antimicrob Agents Chemother. 2019;63:e01126-19.
Gupta AK, Cooper EA, Summerbell RC, Nakrieko KA. Utility of polymerase chain reaction for assessment of onychomycosis during topical therapy. Int J Dermatol. 2022;61:1385-9.
Arendrup MC, Jørgensen KM, Guinea J, Lagrou K, Chryssanthou E, Hayette MP, et al. Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. J Antimicrob Chemother. 2020;75:1807-19.
Arendrup MC, Jørgensen KM, Guinea J, Lagrou K, Chryssanthou E, Hayette MP, et al. Comment on: Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. J Antimicrob Chemother. 2022;77:1212-3.
Gupta AK, Venkataraman M, Renaud HJ, Summerbell R, Shear NH, Piguet V. A paradigm shift in the treatment and management of onychomycosis. Skin Appendage Disord. 2021;7:251-8.
Sugiura K, Masumoto A, Tachibana H, Tatsumi Y. In vitro combination effect of topical and oral anti-onychomycosis drugs on Trichophyton rubrum and Trichophyton interdigitale. J Fungi. 2021;7:208.
Babu PR, Pravin A, Deshmukh G, Dhoot D, Samant A, Kotak B. Efficacy and safety of terbinafine 500 mg once daily in patients with dermatophytosis. Indian J Dermatol. 2017;62:395.
van der Schroeff JG, Cirkel PK, Crijns MB, Van Dijk TJ, Govaert FJ, Groeneweg DA, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol. 1992;126(Suppl 39):36-9.
Watanabe S, Tsubouchi I, Okubo A. Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: a multicenter, double-blind, randomized phase III study. J Dermatol. 2018;45:1151-9.
Stary A, Sarnow E. Fluconazole in the treatment of tinea corporis and tinea cruris. Dermatology. 1998;196:237-41.
Spriet I, Lambrecht C, Lagrou K, Verhamme B. Successful eradication of Scytalidium dimidiatum-induced ungual and cutaneous infection with voriconazole. Eur J Dermatol. 2012;22:197-9.
Scher RK, Breneman D, Rich P, Savin RC, Feingold DS, Konnikov N, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38:S77-86.
Rich P, Scher RK, Breneman D, Savin RC, Feingold DS, Konnikov N, et al. Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38:S103-9.
Nofal A, Fawzy MM, El-Hawary EE. Successful treatment of resistant onychomycosis with voriconazole in a liver transplant patient. Dermatol Ther. 2020;33:e14014.
Khurana A, Agarwal A, Agrawal D, Sardana K, Singh A, Chowdhary A. Multidrug resistant tinea corporis/cruris: response to voriconazole. J Med Mycol. 2022;32:101306.
Khurana A, Agarwal A, Agrawal D, Panesar S, Ghadlinge M, Sardana K, et al. Effect of different itraconazole dosing regimens on cure rates, treatment duration, safety, and relapse rates in adult patients with tinea corporis/cruris: a randomized clinical trial. JAMA Dermatol. 2022;158:1269-78.
Khondker L. Efficacy and safety of voriconazole in the treatment failure cases of dermatophytosis. Gulf J Dermatol Venereol. 2020;27:24-30.
Havu V, Brandt H, Heikkilä H, Hollmen A, Oksman R, Rantanen T, et al. Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison. Br J Dermatol. 1999;140:96-101.
Gupta AK, Renaud HJ, Quinlan EM, Shear NH, Piguet V. The growing problem of antifungal resistance in onychomycosis and other superficial mycoses. Am J Clin Dermatol. 2021;22:149-57.
Gueneau R, Joannard B, Haddad N, Alby F, Jullien V, Schlatter J, et al. Extensive dermatophytosis caused by terbinafine-resistant Trichophyton indotineae, successfully treated with topical voriconazole. Int J Antimicrob Agents. 2022;60:106677.
Elewski B, Pollak R, Ashton S, Rich P, Schlessinger J, Tavakkol A. A randomized, placebo-and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol. 2012;166:389-98.
Elewski B, Brand S, Degenhardt T, Curelop S, Pollak R, Schotzinger R, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail. Br J Dermatol. 2021;184:270-80.
Drake L, Babel D, Stewart DM, Rich P, Ling MR, Breneman D, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. J Am Acad Dermatol. 1998;38:S87-94.
Doncker PD, Gupta AK, Marynissen G, Stoffels P, Heremans A. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol. 1997;37:969-74.
De Doncker P, Decroix J, Pierard GE, Roelant D, Woestenborghs R, Jacqmin P, et al. Antifungal pulse therapy for onychomycosis: a pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol. 1996;132:34-41.
Al-Hatmi AM, Bonifaz A, Calderón L, Curfs-Breuker I, Meis JF, van Diepeningen AD, et al. Proximal subungual onychomycosis caused by Fusarium falciforme successfully cured with posaconazole. Br J Dermatol. 2015;173:253-5.
Gupta AK, Taborda PR, Sanzovo AD. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol. 2002;40:529-34.
Chapman SW, Pappas P, Kauffmann C, Smith EB, Dietze R, Tiraboschi-Foss N, et al. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day(−1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses. 2004;47:62-8.
Esterre P, Inzan C, Ratsioharana M, Andriantsimahavandy A, Raharisolo C, Randrianiaina E, et al. A multicentre trial of terbinafine in patients with chromoblastomycosis: effect on clinical and biological criteria. J Dermatolog Treat. 1998;9:S29-34.
Diflucan (fluconazole). European Medicine Agency. 2012. [cited 16 April 2023]. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/diflucan
Gupta AK, Foley KA, Versteeg SG. New antifungal agents and new formulations against dermatophytes. Mycopathologia. 2017;182:127-41.
Mendes NS, Bitencourt TA, Sanches PR, Silva-Rocha R, Martinez-Rossi NM, Rossi A. Transcriptome-wide survey of gene expression changes and alternative splicing in Trichophyton rubrum in response to undecanoic acid. Sci Rep. 2018;8:2520.
Paião FG, Segato F, Cursino-Santos JR, Peres NT, Martinez-Rossi NM. Analysis of Trichophyton rubrum gene expression in response to cytotoxic drugs. FEMS Microbiol Lett. 2007;271:180-6.
Khurana A, Masih A, Chowdhary A, Sardana K, Borker S, Gupta A, et al. Correlation of in vitro susceptibility based on MICs and squalene epoxidase mutations with clinical response to terbinafine in patients with tinea corporis/cruris. Antimicrob Agents Chemother. 2018;62:e01038-18.
Sacheli R, Hayette MP. Antifungal resistance in dermatophytes: genetic considerations, clinical presentations and alternative therapies. J Fungi. 2021;7:983-1006.
Noxafil (posaconazole) 40 mg/mL oral suspension. European Medicine Agency. 2010. [cited 16 April 2023]. Available from: https://www.ema.europa.eu/en/documents/product-information/noxafil-epar-product-information_en.pdf
Posaconazole Accord 100 mg gastro-resistant tablets. European Medicine Agency. 2019. [cited 16 April 2023]. Available from: https://www.ema.europa.eu/en/documents/product-information/posaconazole-accord-epar-product-information_en.pdf
VFEND (voriconazole) 50 mg film-coated tablets & VFEND (voriconazole) 200 mg film-coated tablets. European Medicine Agency. 2012. [cited 16 April 2023]. Available from: https://www.ema.europa.eu/en/documents/product-information/vfend-epar-product-information_en.pdf
Voriconazole Accord 50 mg film-coated tablets & Voriconazole Accord 200 mg film-coated tablets. European Medicine Agency. 2018. [cited 16 April 2023]. Available from: https://www.ema.europa.eu/en/documents/product-information/voriconazole-accord-epar-product-information_en.pdf
European Medicines Agency Decision on Oteseconazole. 2021. [cited 16 April 2023]. Available from: https://www.ema.europa.eu/en/documents/pip-decision/p/0460/2021-ema-decision-29-october-2021-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
Highlights of prescribing information, VIVJOA™ (oteseconazole) capsules, for oral use (US FDA). 2022. [cited 16 April 2023]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215888s000lbl.pdf
Leeyaphan C, Suiwongsa B, Komesmuneeborirak P, Kiratiwongwan R, Wongdama S, Prasong W, et al. Effectiveness and safety of topical amphotericin B in 30% dimethyl sulfoxide cream versus 30% dimethyl sulfoxide cream for nondermatophyte onychomycosis treatment: a pilot study. Indian J Dermatol Venereol Leprol. 2022;88:494-9.
Haghani I, Shams-Ghahfarokhi M, Dalimi Asl A, Shokohi T, Hedayati MT. Prevalence, genetic diversity and antifungal susceptibility profiles of F. fujikuroi, F. solani and Fusarium incarnatum-equiseti species complexes from onychomycosis in north of Iran. Mycoses. 2022;65:1030-9.
Edwards JE Jr, Schwartz MM, Schmidt CS, Sobel JD, Nyirjesy P, Schodel F, et al. A fungal immunotherapeutic vaccine (NDV-3A) for treatment of recurrent vulvovaginal candidiasis-A phase 2 randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2018;66:1928-36.
Sandison T, Ong V, Lee J, Thye D. Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults. Antimicrob Agents Chemother. 2017;61:e01627-16.
Miesel L, Lin KY, Ong V. Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: insights on the PK/PD pharmacometrics of rezafungin efficacy. Pharmacol Res Perspect. 2019;7:e00546.
Garcia-Effron G. Rezafungin-mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins. J Fungi. 2020;6:262-85.
Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M. Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). J Antimicrob Chemother. 2013;68:858-63.
Oliver JD, Sibley GEM, Beckmann N, Dobb KS, Slater MJ, McEntee L, et al. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. Proc Natl Acad Sci USA. 2016;113:12809-14.
Hata K, Horii T, Miyazaki M, Watanabe NA, Okubo M, Sonoda J, et al. Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis. Antimicrob Agents Chemother. 2011;55:4543-51.
Lanteri CA, Trumpower BL, Tidwell RR, Meshnick SR. DB75, a novel trypanocidal agent, disrupts mitochondrial function in Saccharomyces cerevisiae. Antimicrob Agents Chemother. 2004;48:3968-74.
Yamada E, Nishikawa H, Nomura N, Mitsuyama J. T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena. Antimicrob Agents Chemother. 2010;54:3630-4.
Yamashita K, Miyazaki T, Fukuda Y, Mitsuyama J, Saijo T, Shimamura S, et al. The novel arylamidine T-2307 selectively disrupts yeast mitochondrial function by inhibiting respiratory chain complexes. Antimicrob Agents Chemother. 2019;63:e00374-19.
Nishikawa H, Yamada E, Shibata T, Uchihashi S, Fan H, Hayakawa H, et al. Uptake of T-2307, a novel arylamidine, in Candida albicans. J Antimicrob Chemother. 2010;65:1681-7.
Mitsuyama J, Nomura N, Hashimoto K, Yamada E, Nishikawa H, Kaeriyama M, et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother. 2008;52:1318-24.
Shen JJ, Jemec GBE, Arendrup MC, Saunte DML. Photodynamic therapy treatment of superficial fungal infections: a systematic review. Photodiagnosis Photodyn Ther. 2020;31:101774.
Johnson MD, Lewis RE, Dodds Ashley ES, Ostrosky-Zeichner L, Zaoutis T, Thompson GR, et al. Core Recommendations for Antifungal Stewardship: a statement of the Mycoses Study Group Education and Research Consortium. J Infect Dis. 2020;222:S175-S198.
Born KB, Leis JA, Gold WL, Levinson W. "Choosing Wisely Canada" and antimicrobial stewardship: a shared focus on reducing unnecessary care. Can Commun Dis Rep. 2015;41:9-13.
Singh S, Menon VP, Mohamed ZU, Kumar VA, Nampoothiri V, Sudhir S, et al. Implementation and Impact of an Antimicrobial Stewardship Program at a Tertiary Care Center in South India. Open Forum Infect Dis. 2019;6:6.
Lachenmayr SJ, Strobach D, Berking S, Horns H, Berger K, Ostermann H. Improving quality of antifungal use through antifungal stewardship interventions. Infection. 2019;47:603-10.
Nivoix Y, Launoy A, Lutun P, Moulin J-C, Phai Pang K-A, Fornecker L-M, et al. Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. J Antimicrob Chemother. 2012;67:2506-13.
World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS). 2022. [cited 2022 November 8]. Available from: https://www.who.int/initiatives/glass
Centers for Disease Control and Prevention. Antimicrobial-resistant fungi. 2022. [cited 2022 November 8]. Available from: https://www.cdc.gov/fungal/antifungal-resistance.html#tackling